JP2021523894A - カナキヌマブの使用 - Google Patents

カナキヌマブの使用 Download PDF

Info

Publication number
JP2021523894A
JP2021523894A JP2020562124A JP2020562124A JP2021523894A JP 2021523894 A JP2021523894 A JP 2021523894A JP 2020562124 A JP2020562124 A JP 2020562124A JP 2020562124 A JP2020562124 A JP 2020562124A JP 2021523894 A JP2021523894 A JP 2021523894A
Authority
JP
Japan
Prior art keywords
canakinumab
patient
less
hscrp
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020562124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523894A5 (enExample
Inventor
シーカー，マティアス
ミンデホルム，リンダ
プレストガード，ジェンス
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2021523894A publication Critical patent/JP2021523894A/ja
Publication of JP2021523894A5 publication Critical patent/JP2021523894A5/ja
Priority to JP2023034283A priority Critical patent/JP7713983B2/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020562124A 2018-05-09 2018-08-24 カナキヌマブの使用 Withdrawn JP2021523894A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023034283A JP7713983B2 (ja) 2018-05-09 2023-03-07 カナキヌマブの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862669071P 2018-05-09 2018-05-09
US62/669,071 2018-05-09
PCT/IB2018/056455 WO2019215484A1 (en) 2018-05-09 2018-08-24 Use of canakinumab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023034283A Division JP7713983B2 (ja) 2018-05-09 2023-03-07 カナキヌマブの使用

Publications (2)

Publication Number Publication Date
JP2021523894A true JP2021523894A (ja) 2021-09-09
JP2021523894A5 JP2021523894A5 (enExample) 2021-10-21

Family

ID=63638190

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562124A Withdrawn JP2021523894A (ja) 2018-05-09 2018-08-24 カナキヌマブの使用
JP2023034283A Active JP7713983B2 (ja) 2018-05-09 2023-03-07 カナキヌマブの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023034283A Active JP7713983B2 (ja) 2018-05-09 2023-03-07 カナキヌマブの使用

Country Status (12)

Country Link
US (1) US20210371511A1 (enExample)
EP (1) EP3790576A1 (enExample)
JP (2) JP2021523894A (enExample)
KR (1) KR20210008847A (enExample)
CN (2) CN119746057A (enExample)
AU (1) AU2018422406A1 (enExample)
BR (1) BR112020022576A2 (enExample)
CA (1) CA3098277A1 (enExample)
CL (1) CL2020002881A1 (enExample)
MX (1) MX2020011909A (enExample)
TW (1) TW201946652A (enExample)
WO (1) WO2019215484A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112402359A (zh) * 2020-11-04 2021-02-26 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症因子治疗痛风急性发作的聚合物微针及制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004506448A (ja) * 2000-08-22 2004-03-04 ノバルティス　アクチエンゲゼルシャフト ヒトＩＬ−１βに対する抗体
JP2016540761A (ja) * 2013-12-02 2016-12-28 アッヴィ・インコーポレイテッド 変形性関節症を治療するための組成物及び方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
PL2848258T3 (pl) 2005-10-26 2018-06-29 Novartis Ag Leczenie rodzinnej gorączki śródziemnomorskiej przeciwciałami przeciwko IL-1beta
HRP20251174T1 (hr) * 2010-11-05 2025-11-21 Novartis Ag Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista
BR112014007253A2 (pt) * 2011-09-30 2017-03-28 Novartis Ag uso de anticorpos que se ligam a il-1beta
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
AU2018287519B2 (en) * 2017-06-22 2021-07-22 Novartis Ag IL-1beta binding antibodies for use in treating cancer
CN107723310B (zh) * 2017-10-19 2024-01-09 北京睿诚海汇健康科技有限公司 植物作为宿主在表达卡那抗体中的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004506448A (ja) * 2000-08-22 2004-03-04 ノバルティス　アクチエンゲゼルシャフト ヒトＩＬ−１βに対する抗体
JP2016540761A (ja) * 2013-12-02 2016-12-28 アッヴィ・インコーポレイテッド 変形性関節症を治療するための組成物及び方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARTHROSCOPY : THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, vol. Vol.26, No.8, pp.1096-1104, JPN6022038428, 2010, ISSN: 0004873286 *
CYTOKINE, vol. Vol.71, pp.165-172, JPN6022038427, 2015, ISSN: 0004873285 *
OSTEOARTHRITIS AND CARTILAGE, vol. Vol.15, pp.516-523, JPN6022038429, 2007, ISSN: 0004873287 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. Vol.12, pp.1119-1131, JPN6022038430, 2017, ISSN: 0004873288 *

Also Published As

Publication number Publication date
BR112020022576A2 (pt) 2021-02-09
MX2020011909A (es) 2021-01-29
TW201946652A (zh) 2019-12-16
KR20210008847A (ko) 2021-01-25
AU2018422406A1 (en) 2020-11-12
CL2020002881A1 (es) 2021-05-14
JP2023071904A (ja) 2023-05-23
CA3098277A1 (en) 2019-11-14
WO2019215484A1 (en) 2019-11-14
EP3790576A1 (en) 2021-03-17
US20210371511A1 (en) 2021-12-02
JP7713983B2 (ja) 2025-07-28
CN119746057A (zh) 2025-04-04
CN112584857A (zh) 2021-03-30

Similar Documents

Publication Publication Date Title
JP6515168B2 (ja) Ｉｌ−１７アンタゴニストを用いて関節リウマチを治療する方法
JP7389077B2 (ja) インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP2021503476A (ja) Ｉｌ−１７アンタゴニストを用いて化膿性汗腺炎を治療すること
US20150291689A1 (en) Compositions and Methods for Treating Rheumatoid Arthritis
US20150203592A1 (en) Compositions and methods for treating osteoarthritis
EP4025248A1 (en) Treatment of liver disease or disorder comprising actrii receptor antagonists
US20200231666A1 (en) Treatment paradigm
US20230331834A1 (en) Method of treating tendinopathy using interleukin-17 (il-17)
JP7713983B2 (ja) カナキヌマブの使用
JP2025516723A (ja) インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
WO2020039401A1 (en) Treatment comprising il-1βeta binding antibodies and combinations thereof
US20250228864A1 (en) Therapies for the treatment of inflammatory bowel disease
RU2852738C1 (ru) Способы лечения аутоиммунных заболеваний с применением антагонистов интерлейкина-17 (il-17)
WO2025072725A1 (en) Methods for the treatment of cardiovascular disease
WO2025259644A1 (en) Use of an immunoconjugate for the treatment of gastroesophageal cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221114

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20230322